These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1212 related items for PubMed ID: 19922879

  • 1. Comparison of insulin detemir and insulin glargine in a basal-bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: a 52-week, multinational, randomized, open-label, parallel-group, treat-to-target noninferiority trial.
    Heller S, Koenen C, Bode B.
    Clin Ther; 2009 Oct; 31(10):2086-97. PubMed ID: 19922879
    [Abstract] [Full Text] [Related]

  • 2. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes.
    Hollander P, Cooper J, Bregnhøj J, Pedersen CB.
    Clin Ther; 2008 Nov; 30(11):1976-87. PubMed ID: 19108786
    [Abstract] [Full Text] [Related]

  • 3. Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen.
    Russell-Jones D, Simpson R, Hylleberg B, Draeger E, Bolinder J.
    Clin Ther; 2004 May; 26(5):724-36. PubMed ID: 15220016
    [Abstract] [Full Text] [Related]

  • 4. Randomized, open-label, parallel-group evaluations of basal-bolus therapy versus insulin lispro premixed therapy in patients with type 2 diabetes mellitus failing to achieve control with starter insulin treatment and continuing oral antihyperglycemic drugs: a noninferiority intensification substudy of the DURABLE trial.
    Miser WF, Arakaki R, Jiang H, Scism-Bacon J, Anderson PW, Fahrbach JL.
    Clin Ther; 2010 May; 32(5):896-908. PubMed ID: 20685497
    [Abstract] [Full Text] [Related]

  • 5. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial.
    Barnett AH, Burger J, Johns D, Brodows R, Kendall DM, Roberts A, Trautmann ME.
    Clin Ther; 2007 Nov; 29(11):2333-48. PubMed ID: 18158075
    [Abstract] [Full Text] [Related]

  • 6. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes.
    Rosenstock J, Davies M, Home PD, Larsen J, Koenen C, Schernthaner G.
    Diabetologia; 2008 Mar; 51(3):408-16. PubMed ID: 18204830
    [Abstract] [Full Text] [Related]

  • 7. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes.
    Hermansen K, Fontaine P, Kukolja KK, Peterkova V, Leth G, Gall MA.
    Diabetologia; 2004 Apr; 47(4):622-9. PubMed ID: 15298338
    [Abstract] [Full Text] [Related]

  • 8. Once-daily initiation of basal insulin as add-on to metformin: a 26-week, randomized, treat-to-target trial comparing insulin detemir with insulin glargine in patients with type 2 diabetes.
    Meneghini L, Kesavadev J, Demissie M, Nazeri A, Hollander P.
    Diabetes Obes Metab; 2013 Aug; 15(8):729-36. PubMed ID: 23421331
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Deleterious outcomes after abrupt transition from insulin glargine to insulin detemir in patients with type 1 diabetes mellitus.
    Kabadi UM.
    Clin Drug Investig; 2008 Aug; 28(11):697-701. PubMed ID: 18840012
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Higher insulin detemir doses are required for the similar glycemic control: comparison of insulin detemir and glargine in children with type 1 diabetes mellitus.
    Abalı S, Turan S, Atay Z, Güran T, Haliloğlu B, Bereket A.
    Pediatr Diabetes; 2015 Aug; 16(5):361-6. PubMed ID: 25039448
    [Abstract] [Full Text] [Related]

  • 16. Long-term efficacy and safety of insulin detemir compared to Neutral Protamine Hagedorn insulin in patients with Type 1 diabetes using a treat-to-target basal-bolus regimen with insulin aspart at meals: a 2-year, randomized, controlled trial.
    Bartley PC, Bogoev M, Larsen J, Philotheou A.
    Diabet Med; 2008 Apr; 25(4):442-9. PubMed ID: 18387078
    [Abstract] [Full Text] [Related]

  • 17. Comparison of insulin detemir and insulin glargine in subjects with Type 1 diabetes using intensive insulin therapy.
    Pieber TR, Treichel HC, Hompesch B, Philotheou A, Mordhorst L, Gall MA, Robertson LI.
    Diabet Med; 2007 Jun; 24(6):635-42. PubMed ID: 17381500
    [Abstract] [Full Text] [Related]

  • 18. Comparison of once- versus twice-daily administration of insulin detemir, used with mealtime insulin aspart, in basal-bolus therapy for type 1 diabetes: assessment of detemir administration in a progressive treat-to-target trial (ADAPT).
    Le Floch JP, Lévy M, Mosnier-Pudar H, Nobels F, Laroche S, Gonbert S, Eschwege E, Fontaine P, Assessment of Detemir Administration in Progressive Treat-to-Target Trial (ADAPT) Study Group.
    Diabetes Care; 2009 Jan; 32(1):32-7. PubMed ID: 18945928
    [Abstract] [Full Text] [Related]

  • 19. Fast-Acting Insulin Aspart Improves Glycemic Control in Basal-Bolus Treatment for Type 1 Diabetes: Results of a 26-Week Multicenter, Active-Controlled, Treat-to-Target, Randomized, Parallel-Group Trial (onset 1).
    Russell-Jones D, Bode BW, De Block C, Franek E, Heller SR, Mathieu C, Philis-Tsimikas A, Rose L, Woo VC, Østerskov AB, Graungaard T, Bergenstal RM.
    Diabetes Care; 2017 Jul; 40(7):943-950. PubMed ID: 28356319
    [Abstract] [Full Text] [Related]

  • 20. The 12-month efficacy and safety of insulin detemir and NPH insulin in basal-bolus therapy for the treatment of type 1 diabetes.
    Standl E, Lang H, Roberts A.
    Diabetes Technol Ther; 2004 Oct; 6(5):579-88. PubMed ID: 15628811
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 61.